What exactly did BNP Paribas do on March 12, 2026 for WOOF analyst rating?

BNP Paribas maintained an **Underperform** rating on March 12, 2026 and lowered the price target to **$2.18**, according to a StreetInsider note published at **12:16 PM**.

How should investors interpret the lowered WOOF price target?

A lowered **WOOF price target** indicates the analyst expects less upside based on revised forecasts or multiples; investors should reassess entry points and risk given the Underperform stance.

Does this WOOF analyst rating mean sell the stock?

An Underperform from BNP Paribas signals caution but is not an absolute sell signal; investors should combine the WOOF analyst rating with fundamentals, Meyka’s C+ grade, and personal risk tolerance.

Where can I read the analyst note referenced in this article?

The BNP Paribas note and price target change were reported by StreetInsider; see the coverage at [StreetInsider](https://www.streetinsider.com/Analyst+Comments/Petco+Heath+%26+Wellness+Co.+Inc.+%28WOOF%29+PT+Lowered+to+%242.18+at+BNP+Paribas+Exane/26151670.html).

Analyst Ratings

BNP Paribas Maintains Underperform on Petco Health and Wellness (WOOF) March 2026

ByHuzaifa Zahoor March 13, 2026

BNP Paribas maintained an Underperform rating on Petco Health and Wellness Company, Inc. (WOOF) on March 12, 2026, a key WOOF analyst rating update that included a lowered price target. BNP Paribas Exane cut the target to $2.18 while keeping the rating unchanged at the Underperform level, according to a StreetInsider report. This action is the only public rating change reported on March 12, 2026, and it signals continued caution from at least one major European broker amid Petco’s recent performance and outlook.